Project documents | Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661] | Guidance | NICE

Documents

Documents created during the development process.

Invitation to participate

Final scope (PDF 176 KB)

Published:

19 February 2020
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 444 KB)

Published:

19 February 2020
Equality impact assessment (Scoping) (PDF 126 KB)

Published:

19 February 2020
Final stakeholder list (PDF 192 KB)

Published:

19 February 2020

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope pre referral (PDF 229 KB)

Published:

19 December 2019
Draft matrix pre referral (PDF 181 KB)

Published:

19 December 2019